Viral Inactivation Market
Viral Inactivation Market Size, Share & Trends Analysis Report, By Product (Kits & Reagents, Viral Inactivation Systems), By Molecule Type (Monoclonal Antibodies, Vaccines), By End User (Biopharmaceutical Companies, CDMOs/CMOs), Forecast Period (2026–2035)
Industry Overview
Viral Inactivation market was valued at $725 million in 2025 and is projected to reach $1,732 million by 2035, registering a compound annual growth rate (CAGR) of 9.1% during the forecast period 2026–2035. Expansion of biopharmaceutical manufacturing and stringent regulatory requirements for viral safety in biologics underpin the market's robust expansion trajectory. Key end-use industries, including Biopharmaceutical Companies, CDMOs/CMOs, and CROs, continue to generate sustained demand for viral inactivation solutions globally. The market is witnessing rapid technological evolution, driven by a combination of regulatory mandates, investment in innovation, and expanding industrial applications across mature and emerging economies alike. North America currently holds the largest market share, while Asia-Pacific is expected to exhibit the fastest growth rate over the forecast horizon, fueled by industrial expansion and favorable government policies.
Market Dynamics
Expanding Biologics Pipeline and Regulatory Mandates for Viral Safety Driving Market Growth
The global Viral Inactivation market is experiencing significant growth momentum, driven by the expansion of biopharmaceutical manufacturing and stringent regulatory requirements for viral safety in biologics. According to authoritative industry data from relevant international organizations, demand across key end-use segments has been growing at an accelerated pace since 2022. Companies operating within the viral inactivation value chain have made strategic investments in R&D and manufacturing capacity expansions between 2023 and 2026 to address this demand. The adoption of advanced materials, digitalization, and sustainability-focused design principles is further reshaping the competitive landscape, with market leaders deploying differentiated product strategies to capture premium market segments. Emerging markets in Asia-Pacific, the Middle East, and Latin America are increasingly contributing to global demand growth, supported by infrastructure investment programs, urbanization, and evolving regulatory frameworks aligned with international standards. These dynamics collectively reinforce a positive long-term demand outlook for the viral inactivation market through 2035.
High Validation Costs and Technical Complexity of Viral Clearance Studies Restrain Adoption
Despite robust growth drivers, the global Viral Inactivation market faces several headwinds that could temper the pace of expansion. High capital investment requirements and complex supply chain structures present barriers to entry for smaller manufacturers and limit rapid capacity scaling. Volatility in raw material and component costs, exacerbated by geopolitical tensions and logistics disruptions, continues to pressure operating margins across the value chain. Stringent regulatory compliance requirements across multiple jurisdictions add to operational complexity and time-to-market challenges. Furthermore, technological transitions within key end-use industries demand continuous product innovation, requiring sustained R&D investment that not all market participants can sustain. Companies are responding to these challenges through supply chain diversification, vertical integration strategies, strategic partnerships, and investment in automation and digital manufacturing capabilities to optimize cost structures and enhance operational resilience.
Market Segmentation
- Based on the Product, the global Viral Inactivation market is segmented into Kits & Reagents, Viral Inactivation Systems, Consumables, and Services.
- Based on the Molecule Type, the global Viral Inactivation market is segmented into Monoclonal Antibodies, Vaccines, Blood & Plasma Products, Recombinant Proteins, Cell & Gene Therapy Products, and Other.
- Based on the End User, the global Viral Inactivation market is segmented into Biopharmaceutical Companies, CDMOs/CMOs, CROs, and Academic & Research Institutes.
Biopharmaceutical Companies Segment Leads the Market
The Biopharmaceutical Companies segment currently accounts for the largest share of the global Viral Inactivation market, underpinned by widespread adoption across primary end-use industries and well-established supply chain infrastructure. Demand drivers for this segment include broad applicability, cost competitiveness relative to alternative solutions, and strong brand-level investments by leading market participants. Between 2022 and 2026, key companies within this segment have pursued strategic product portfolio expansions, geographic market entries, and technology licensing agreements to consolidate their market positions. Industry stakeholders have also benefited from favorable regulatory frameworks in key markets, including the United States, Germany, and Japan, which have reinforced adoption across commercial and industrial end-user categories. The Biopharmaceutical Companies segment is expected to maintain its leadership through the forecast period, supported by sustained capital expenditure in infrastructure development and an expanding base of installed equipment requiring replacement consumables and service solutions.
Cell & Gene Therapy Products Segment to Record Strong Growth
The Cell & Gene Therapy Products segment is projected to register the strongest growth rate within the global Viral Inactivation market over the 2026–2035 forecast period. This segment's rapid expansion is driven by accelerating technological innovation, increasing investment from both established incumbents and new market entrants, and growing demand from emerging application areas not yet fully penetrated by conventional alternatives. Venture capital and private equity investment flows into technology startups operating within this segment have been significant since 2022, reflecting high commercial expectations for next-generation solutions. Strategic collaborations between technology developers and large-scale manufacturers have accelerated commercialization timelines. Furthermore, supportive government programs and procurement initiatives across multiple geographies are providing early-stage demand anchors for cell & gene therapy product applications, with volume scale-up anticipated to drive meaningful cost reductions that will further broaden total addressable market access through 2035.
Regional Outlook
The global Viral Inactivation market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).
United States Leads the Viral Inactivation Market
The United States dominates the global viral inactivation market, anchored by the world's largest biopharmaceutical manufacturing base and strict viral safety regulatory frameworks established by the U.S. Food and Drug Administration (FDA). According to the FDA, the number of licensed biologics products has grown consistently, with over 100 new biologics license applications (BLAs) reviewed annually in recent years. PhRMA data indicates U.S. biopharmaceutical companies invested over $102 billion in R&D in 2023, fueling downstream demand for viral safety testing, inactivation systems, and filtration consumables.
China to Record Strong Growth
China is emerging as a high-growth market for viral inactivation, driven by the rapid expansion of domestic biopharmaceutical manufacturing capacity and the increasing alignment of Chinese biologics regulatory standards with ICH Q5A guidelines on viral safety evaluation. According to the National Medical Products Administration (NMPA) of China, biologics approval volumes have grown significantly as domestic CDMOs scale operations. WuXi Biologics and Lonza's Guangzhou facility expansions reflect growing CDMO infrastructure investments that require compliant viral clearance workflows.
Competitive Landscape
The global Viral Inactivation market is characterized by a moderately consolidated competitive structure, with a mix of global technology leaders, diversified industrial conglomerates, and specialized niche players competing across product performance, pricing, distribution reach, and service capabilities. The five leading companies – Merck KGaA (MilliporeSigma), Sartorius AG, Charles River Laboratories, Cytiva, Thermo Fisher Scientific – collectively account for a significant share of global market revenues, leveraging their scale advantages in R&D investment, manufacturing efficiency, and established customer relationships. Competitive dynamics are intensifying as new entrants deploy disruptive technologies and as established players respond through M&A, product innovation pipelines, and strategic partnerships. Supply chain resilience and the ability to offer integrated solutions encompassing products, software, and services are increasingly differentiating top-tier competitors. Geopolitical considerations are also shaping competitive strategy, with companies pursuing regional manufacturing footprint diversification to reduce exposure to trade policy risks and logistical vulnerabilities identified during the 2020–2022 period.
Recent Developments
- Merck KGaA (MilliporeSigma) launched its Viresolve® Pro Shock viral filtration system, enabling single-use high-throughput viral clearance for mAb manufacturing processes, addressing scale-up needs in commercial biologics production.
- Sartorius AG acquired a viral safety testing services firm to vertically integrate its viral inactivation product portfolio with analytical services, strengthening its end-to-end bioprocessing value proposition.
- Cytiva partnered with a leading Japanese plasma fractionation company to deploy its scalable UV-C viral inactivation platform across two GMP manufacturing sites, expanding Asia-Pacific commercial footprint.
- Charles River Laboratories expanded its viral safety testing laboratory capacity in Edinburgh, UK by 40%, responding to increased demand from European CDMOs and cell & gene therapy developers.
- Repligen Corporation introduced enhanced single-use virus filtration capsule formats for its XCell® ATF platform, targeting continuous bioprocessing applications in high-titer mAb manufacturing.
- WuXi Biologics commissioned a dedicated viral vector manufacturing and inactivation suite at its Wuxi facility, targeting growing demand from cell & gene therapy developers requiring GMP-compliant viral clearance.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Viral Inactivation market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying 'who-stands-where' in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Viral Inactivation Market Sales Analysis – Product | Molecule Type | End User ($ Million)
- Viral Inactivation Market Sales Performance of Top Countries
1.1 Research Methodology
- Primary Research Approach
- Secondary Research Approach
1.2 Market Snapshot
- Market Overview and Insights
2.1 Scope of the Study
2.2 Analyst Insight & Current Market Trends
2.2.1 Key Viral Inactivation Market Trends
2.2.2 Market Recommendations
2.3 Porter's Five Forces Analysis for the Viral Inactivation Market
2.3.1 Competitive Rivalry
2.3.2 Threat of New Entrants
2.3.3 Bargaining Power of Suppliers
2.3.4 Bargaining Power of Buyers
2.3.5 Threat of Substitutes
- Market Determinants
3.1 Market Drivers
3.1.1 Drivers For Global Viral Inactivation Market: Impact Analysis
3.2 Market Pain Points and Challenges
3.2.1 Restraints For Global Viral Inactivation Market: Impact Analysis
3.3 Market Opportunities
3.3.1 Opportunities For Global Viral Inactivation Market: Impact Analysis
- Competitive Landscape
4.1 Competitive Dashboard – Viral Inactivation Market Revenue and Share by Manufacturers
- Viral Inactivation Product Comparison Analysis
- Top Market Player Ranking Matrix
4.2 Key Company Analysis
4.2.1 Merck KGaA (MilliporeSigma)
4.2.1.1 Overview
4.2.1.2 Product Portfolio
4.2.1.3 Financial Analysis
4.2.1.4 SWOT Analysis
4.2.1.5 Business Strategy
4.2.2 Sartorius AG
4.2.2.1 Overview
4.2.2.2 Product Portfolio
4.2.2.3 Financial Analysis
4.2.2.4 SWOT Analysis
4.2.2.5 Business Strategy
4.2.3 Charles River Laboratories
4.2.3.1 Overview
4.2.3.2 Product Portfolio
4.2.3.3 Financial Analysis
4.2.3.4 SWOT Analysis
4.2.3.5 Business Strategy
4.2.4 Cytiva
4.2.4.1 Overview
4.2.4.2 Product Portfolio
4.2.4.3 Financial Analysis
4.2.4.4 SWOT Analysis
4.2.4.5 Business Strategy
4.2.5 Thermo Fisher Scientific
4.2.5.1 Overview
4.2.5.2 Product Portfolio
4.2.5.3 Financial Analysis
4.2.5.4 SWOT Analysis
4.2.5.5 Business Strategy
4.3 Top Winning Strategies by Market Players
4.3.1 Merger and Acquisition
4.3.2 Product Launch
4.3.3 Partnership And Collaboration
- Global Viral Inactivation Market Sales Analysis by Product ($ Million)
5.1 Kits & Reagents
5.2 Viral Inactivation Systems
5.3 Consumables
5.4 Services
- Global Viral Inactivation Market Sales Analysis by Molecule Type ($ Million)
6.1 Monoclonal Antibodies
6.2 Vaccines
6.3 Blood & Plasma Products
6.4 Recombinant Proteins
6.5 Cell & Gene Therapy Products
6.6 Other
- Global Viral Inactivation Market Sales Analysis by End User ($ Million)
7.1 Biopharmaceutical Companies
7.2 CDMOs/CMOs
7.3 CROs
7.4 Academic & Research Institutes
- Regional Analysis
8.1 North American Viral Inactivation Market Sales Analysis – Product | Molecule Type | End User | Country ($ Million)
8.1.1 United States
8.1.2 Canada
8.2 European Viral Inactivation Market Sales Analysis – Product | Molecule Type | End User | Country ($ Million)
8.2.1 UK
8.2.2 Germany
8.2.3 Italy
8.2.4 Spain
8.2.5 France
8.2.6 Switzerland
8.2.7 Nordic Countries
8.2.8 Rest of Europe
8.3 Asia-Pacific Viral Inactivation Market Sales Analysis – Product | Molecule Type | End User | Country ($ Million)
8.3.1 China
8.3.2 Japan
8.3.3 South Korea
8.3.4 India
8.3.5 Australia & New Zealand
8.3.6 ASEAN Countries
8.3.7 Rest of Asia-Pacific
8.4 Rest of the World Viral Inactivation Market Sales Analysis – Product | Molecule Type | End User | Country ($ Million)
8.4.1 Latin America
8.4.2 Middle East and Africa
- Company Profiles
9.1 Asahi Kasei Medical
9.1.1 Quick Facts
9.1.2 Company Overview
9.1.3 Product Portfolio
9.1.4 Business Strategies
9.2 Bio-Rad Laboratories
9.2.1 Quick Facts
9.2.2 Company Overview
9.2.3 Product Portfolio
9.2.4 Business Strategies
9.3 Charles River Laboratories
9.3.1 Quick Facts
9.3.2 Company Overview
9.3.3 Product Portfolio
9.3.4 Business Strategies
9.4 Clean Cells
9.4.1 Quick Facts
9.4.2 Company Overview
9.4.3 Product Portfolio
9.4.4 Business Strategies
9.5 Cytiva
9.5.1 Quick Facts
9.5.2 Company Overview
9.5.3 Product Portfolio
9.5.4 Business Strategies
9.6 Danaher Corporation (Pall Corporation)
9.6.1 Quick Facts
9.6.2 Company Overview
9.6.3 Product Portfolio
9.6.4 Business Strategies
9.7 Donaldson Company
9.7.1 Quick Facts
9.7.2 Company Overview
9.7.3 Product Portfolio
9.7.4 Business Strategies
9.8 Eurofins Scientific
9.8.1 Quick Facts
9.8.2 Company Overview
9.8.3 Product Portfolio
9.8.4 Business Strategies
9.9 Lonza Group
9.9.1 Quick Facts
9.9.2 Company Overview
9.9.3 Product Portfolio
9.9.4 Business Strategies
9.10 Meissner Filtration Products
9.10.1 Quick Facts
9.10.2 Company Overview
9.10.3 Product Portfolio
9.10.4 Business Strategies
9.11 Merck KGaA (MilliporeSigma)
9.11.1 Quick Facts
9.11.2 Company Overview
9.11.3 Product Portfolio
9.11.4 Business Strategies
9.12 Parker Hannifin
9.12.1 Quick Facts
9.12.2 Company Overview
9.12.3 Product Portfolio
9.12.4 Business Strategies
9.13 Rad Source Technologies
9.13.1 Quick Facts
9.13.2 Company Overview
9.13.3 Product Portfolio
9.13.4 Business Strategies
9.14 Repligen Corporation
9.14.1 Quick Facts
9.14.2 Company Overview
9.14.3 Product Portfolio
9.14.4 Business Strategies
9.15 Sartorius AG
9.15.1 Quick Facts
9.15.2 Company Overview
9.15.3 Product Portfolio
9.15.4 Business Strategies
9.16 Sartorius Stedim Biotech
9.16.1 Quick Facts
9.16.2 Company Overview
9.16.3 Product Portfolio
9.16.4 Business Strategies
9.17 SGS SA
9.17.1 Quick Facts
9.17.2 Company Overview
9.17.3 Product Portfolio
9.17.4 Business Strategies
9.18 Texcell
9.18.1 Quick Facts
9.18.2 Company Overview
9.18.3 Product Portfolio
9.18.4 Business Strategies
9.19 Thermo Fisher Scientific
9.19.1 Quick Facts
9.19.2 Company Overview
9.19.3 Product Portfolio
9.19.4 Business Strategies
9.20 WuXi Biologics
9.20.1 Quick Facts
9.20.2 Company Overview
9.20.3 Product Portfolio
9.20.4 Business Strategies
1 Global Viral Inactivation Market Research and Analysis by Product, 2025–2035 ($ Million)
2 Global Kits & Reagents Viral Inactivation Market Research and Analysis by Region, 2025–2035 ($ Million)
3 Global Viral Inactivation Systems Market Research and Analysis by Region, 2025–2035 ($ Million)
4 Global Viral Inactivation Consumables Market Research and Analysis by Region, 2025–2035 ($ Million)
5 Global Viral Inactivation Services Market Research and Analysis by Region, 2025–2035 ($ Million)
6 Global Viral Inactivation Market Research and Analysis by Molecule Type, 2025–2035 ($ Million)
7 Global Monoclonal Antibodies Viral Inactivation Market Research and Analysis by Region, 2025–2035 ($ Million)
8 Global Vaccines Viral Inactivation Market Research and Analysis by Region, 2025–2035 ($ Million)
9 Global Blood & Plasma Products Viral Inactivation Market Research and Analysis by Region, 2025–2035 ($ Million)
10 Global Recombinant Proteins Viral Inactivation Market Research and Analysis by Region, 2025–2035 ($ Million)
11 Global Cell & Gene Therapy Products Viral Inactivation Market Research and Analysis by Region, 2025–2035 ($ Million)
12 Global Other Viral Inactivation Market Research and Analysis by Region, 2025–2035 ($ Million)
13 Global Viral Inactivation Market Research and Analysis by End User, 2025–2035 ($ Million)
14 Global Viral Inactivation For Biopharmaceutical Companies Market Research and Analysis by Region, 2025–2035 ($ Million)
15 Global Viral Inactivation For CDMOs/CMOs Market Research and Analysis by Region, 2025–2035 ($ Million)
16 Global Viral Inactivation For CROs Market Research and Analysis by Region, 2025–2035 ($ Million)
17 Global Academic & Research Institutes Viral Inactivation Market Research and Analysis by Region, 2025–2035 ($ Million)
18 Global Viral Inactivation Market Research and Analysis by Region, 2025–2035 ($ Million)
19 North America Viral Inactivation Market Research and Analysis by Country, 2025–2035 ($ Million)
20 North America Viral Inactivation Market Research and Analysis by Product, 2025–2035 ($ Million)
21 North America Viral Inactivation Market Research and Analysis by Molecule Type, 2025–2035 ($ Million)
22 North America Viral Inactivation Market Research and Analysis by End User, 2025–2035 ($ Million)
23 Europe Viral Inactivation Market Research and Analysis by Country, 2025–2035 ($ Million)
24 Europe Viral Inactivation Market Research and Analysis by Product, 2025–2035 ($ Million)
25 Europe Viral Inactivation Market Research and Analysis by Molecule Type, 2025–2035 ($ Million)
26 Europe Viral Inactivation Market Research and Analysis by End User, 2025–2035 ($ Million)
27 Asia-Pacific Viral Inactivation Market Research and Analysis by Country, 2025–2035 ($ Million)
28 Asia-Pacific Viral Inactivation Market Research and Analysis by Product, 2025–2035 ($ Million)
29 Asia-Pacific Viral Inactivation Market Research and Analysis by Molecule Type, 2025–2035 ($ Million)
30 Asia-Pacific Viral Inactivation Market Research and Analysis by End User, 2025–2035 ($ Million)
31 Rest of the World Viral Inactivation Market Research and Analysis by Region, 2025–2035 ($ Million)
32 Rest of the World Viral Inactivation Market Research and Analysis by Product, 2025–2035 ($ Million)
33 Rest of the World Viral Inactivation Market Research and Analysis by Molecule Type, 2025–2035 ($ Million)
34 Rest of the World Viral Inactivation Market Research and Analysis by End User, 2025–2035 ($ Million)
1 Global Viral Inactivation Market Share by Product, 2025 Vs 2035 (%)
2 Global Viral Inactivation Kits & Reagents Market Share by Region, 2025 Vs 2035 (%)
3 Global Viral Inactivation Systems Market Share by Region, 2025 Vs 2035 (%)
4 Global Viral Inactivation Consumables Market Share by Region, 2025 Vs 2035 (%)
5 Global Viral Inactivation Services Market Share by Region, 2025 Vs 2035 (%)
6 Global Viral Inactivation Market Share by Molecule Type, 2025 Vs 2035 (%)
7 Global Monoclonal Antibodies Viral Inactivation Market Share by Region, 2025 Vs 2035 (%)
8 Global Vaccines Viral Inactivation Market Share by Region, 2025 Vs 2035 (%)
9 Global Blood & Plasma Products Viral Inactivation Market Share by Region, 2025 Vs 2035 (%)
10 Global Recombinant Proteins Viral Inactivation Market Share by Region, 2025 Vs 2035 (%)
11 Global Cell & Gene Therapy Products Viral Inactivation Market Share by Region, 2025 Vs 2035 (%)
12 Global Other Viral Inactivation Market Share by Region, 2025 Vs 2035 (%)
13 Global Viral Inactivation Market Share by End User, 2025 Vs 2035 (%)
14 Global Viral Inactivation For Biopharmaceutical Companies Market Share by Region, 2025 Vs 2035 (%)
15 Global Viral Inactivation For CDMOs/CMOs Market Share by Region, 2025 Vs 2035 (%)
16 Global Viral Inactivation For CROs Market Share by Region, 2025 Vs 2035 (%)
17 Global Viral Inactivation For Academic & Research Institutes Market Share by Region, 2025 Vs 2035 (%)
18 Global Viral Inactivation Market Share by Region, 2025 Vs 2035 (%)
19 Country-Level Viral Inactivation Market Size Comparison, 2025–2035 ($ Million)
20 United States Viral Inactivation Market Size, 2025–2035 ($ Million)
21 Canada Viral Inactivation Market Size, 2025–2035 ($ Million)
22 UK Viral Inactivation Market Size, 2025–2035 ($ Million)
23 France Viral Inactivation Market Size, 2025–2035 ($ Million)
24 Germany Viral Inactivation Market Size, 2025–2035 ($ Million)
25 Italy Viral Inactivation Market Size, 2025–2035 ($ Million)
26 Spain Viral Inactivation Market Size, 2025–2035 ($ Million)
27 Russia Viral Inactivation Market Size, 2025–2035 ($ Million)
28 India Viral Inactivation Market Size, 2025–2035 ($ Million)
29 China Viral Inactivation Market Size, 2025–2035 ($ Million)
30 Japan Viral Inactivation Market Size, 2025–2035 ($ Million)
31 South Korea Viral Inactivation Market Size, 2025–2035 ($ Million)
32 Australia & New Zealand Viral Inactivation Market Size, 2025–2035 ($ Million)
33 ASEAN Viral Inactivation Market Size, 2025–2035 ($ Million)
34 Rest of Asia-Pacific Viral Inactivation Market Size, 2025–2035 ($ Million)
35 Latin America Viral Inactivation Market Size, 2025–2035 ($ Million)
36 Middle East & Africa Viral Inactivation Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of users within the company
